| Literature DB >> 33371082 |
J Jonas1, Vymazal Tomas, T Broz, Miroslav Durila.
Abstract
ABSTRACT: Total hip replacement revision surgery is accompanied by significant blood loss. Using rotational thrombelastometry (ROTEM) perioperatively to diagnose coagulopathy may help to provide rapid aimed therapy and thus decrease blood loss and the consumption of transfusion products. The aim of this case-control study was to find out whether point of care using of ROTEM may reduce blood loss and the consumption of blood transfusion products in hip replacement revision surgery.Data were prospectively collected from patients who underwent hip replacement revision surgery in the period 2017 to 2018 when the management of bleeding and coagulopathy was based on the results of ROTEM. Data were compared with a group of historical controls for the period 2015 to 2016 when bleeding and coagulopathy management was not based on ROTEM results. The consumption of blood transfusion products and perioperative blood loss were compared between the groups.The total number of analyzed patients was 90. Forty five patients were analyzed in the ROTEM group and the same number of patients were analyzed in the non-ROTEM group. Significantly decreased perioperative consumption of fresh frozen plasma and packed red blood cells was found in the ROTEM, as well as decreased perioperative blood loss comparing to non-ROTEM group. All data were statistically different with P < .05.Perioperative management of bleeding and coagulopathy based on the results of ROTEM during hip replacement revision surgery seems to help to decrease perioperative blood loss and the consumption of blood transfusion products, especially fresh frozen plasma.Entities:
Mesh:
Year: 2020 PMID: 33371082 PMCID: PMC7748196 DOI: 10.1097/MD.0000000000023553
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1Examination and therapy schema. Schematic protocol for diagnosis and therapy of coagulopathy. FFP = fresh frozen plasma, PCC = prothrombin complex concentrate, TXA = tranexamic acid.
Characteristics of subjects.
| non-ROTEM | ROTEM | ||
| Subjects (n) | 45 | 45 | |
| Male (n, %) | 15 (33.3%) | 17 (37.8%) | >.05 |
| Female (n, %) | 30 (66.7%) | 28 (62.2%) | |
| Age (years) [median (Q1–Q3)] | 69 (63–74) | 69 (63–74) | >.05 |
| Body weight (kg) [median (Q1–Q3)] | 75 (66–93) | 72 (64–83) | >.05 |
Figure 2Perioperative blood loss. A–blood loss during surgery; B–blood loss during 24 hours after surgery; C–total perioperative blood loss; ∗P < .05; ∗∗P < .01.
Preoperative and postoperative haemoglobin concentration.
| e | ROTEM [median (Q1–Q3)] | ||
| Preoperative Hb (g/L) | 135 (118–140) | 122 (110–133) | <.05 |
| Postoperative Hb (g/L) | 108 (99–119) | 104 (93–118) | >.05 |
| Δ Hb (g/L) | 25 (16–32) | 16 (4–25) | <.05 |
Perioperative FFP consumption.
| e | ROTEM [median (Q1–Q3)] | ||
| FFP consumption during surgery (ml) | 440 (0–558) | 0 (0–0) | <.0001 |
| FFP consumption in 24 hours after surgery (ml) | 0 (0–0) | 0 (0–270) | >.05 |
| total perioperative FFP consumption (ml) | 488 (0–711) | 0 (0–389) | <.05 |
Perioperative PRBC consumption.
| e | ROTEM [median (Q1–Q3)] | ||
| PRBC consumption during surgery (ml) | 527 (0–560) | 0 (0–515) | <.01 |
| PRBC consumption in 24 hours after surgery (ml) | 250 (0–573) | 0 (0–411) | >.05 |
| Total perioperative PRBC consumption (ml) | 577 (254–1131) | 296 (0–586) | <.01 |